Scarica l'app Stockscreener
55.58
1.87%
1.02
Dopo l'orario di chiusura:
55.58
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Supernus (NASDAQ: SUPN) CFO receives performance share unit grant - Stock Titan
Supernus Pharmaceuticals (SUPN) CEO awarded 38,640 performance units - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP gets 3,750 performance share units - Stock Titan
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One-Year Surge? - simplywall.st
Supernus Pharmaceuticals (SUPN) Stock Analysis: A 14.66% Upside and Strong Buy Ratings Shape Investor Outlook - DirectorsTalk Interviews
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One Year Rally? - Yahoo Finance
Envestnet Asset Management Inc. Sells 63,513 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Supernus at TD Cowen Conference: Strategic Diversification Unveiled By Investing.com - Investing.com South Africa
Supernus at TD Cowen Conference: Strategic Diversification Unveiled - Investing.com
Supernus Pharmaceuticals (SUPN) Releases Q4 2025 Earnings: Revenue Up, Operating and Net Losses - Quiver Quantitative
Supernus Pharmaceuticals 2025 10-K: $718.95M Revenue, $(0.68) EPS - TradingView
Sage acquisition and ZURZUVAE strategy reshape Supernus (NASDAQ: SUPN) - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook - simplywall.st
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Vanguard Group Inc. - MarketBeat
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
Supernus (SUPN) SVP reports RSU vesting and tax-withholding share disposition - Stock Titan
Supernus (NASDAQ: SUPN) CFO reports RSU vesting and tax share withholding - Stock Titan
SUPERNUS (NASDAQ: SUPN) executive logs RSU grant and tax share withholding - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals stock hits 52-week high at $57.76 By Investing.com - Investing.com Australia
Supernus (NASDAQ: SUPN) CFO logs RSU vesting, stock awards and tax withholdings - Stock Titan
Director in Supernus (NASDAQ: SUPN) gets 4,475-share stock award - Stock Titan
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Supernus (SUPN) CMO awarded stock as shares withheld for taxes - Stock Titan
TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch - Investing.com Nigeria
Supernus Pharmaceuticals stock hits 52-week high at $57.76 - Investing.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month HighTime to Buy? - MarketBeat
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains - Investing.com Nigeria
Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains By Investing.com - Investing.com UK
Supernus FY25 Total Revenues Up 9%; Guides 17-21% Growth For FY26 - RTTNews
Earnings Call Summary | Supernus Pharmaceuticals(SUPN.US) Q4 2025 Earnings Conference - 富途牛牛
Supernus Pharmaceuticals Swings to Q4 Loss, Revenue Rises - marketscreener.com
Supernus Pharmaceuticals (SUPN) Returns To Quarterly EPS Loss Reinforcing Profitability Concerns - Sahm
Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook Highlights 21% Potential Upside - DirectorsTalk Interviews
Supernus Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highli - GuruFocus
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Millennium Management LLC Increases Stake in Supernus Pharmaceuticals Inc. - GuruFocus
Supernus Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SUPN Sets 2026 Revenue and Earnings Guidance - GuruFocus
Supernus (SUPN) Reports Strong Q4 Revenue and Outlines Future Pl - GuruFocus
Supernus: Fourth Quarter Financial Overview - Bitget
Supernus: Q4 Earnings Snapshot - marketscreener.com
Supernus boosts executive pay with new equity incentives - TipRanks
Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Misses Expectations By $0.48 EPS - MarketBeat
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales - TradingView
Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q4 Revenue $211.6M, vs. FactSet Est of $195.2M - marketscreener.com
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Supernus Pharmaceuticals: Q4 Earnings Insights - Benzinga
Supernus faces earnings test after Q3 shock to profitability - Investing.com India
Supernus faces earnings test after Q3 shock to profitability By Investing.com - Investing.com India
Should I buy Supernus Pharmaceuticals Inc stock nowJuly 2025 Analyst Calls & Verified Technical Trade Signals - baoquankhu1.vn
New Parkinson's drug helps drive Supernus to $719M year - Stock Titan
SUPN | Supernus Pharmaceuticals, Inc. FinancialsIncome Statement - Quiver Quantitative
Supernus Pharmaceuticals to Participate in March Investor Conferences - Bitget
Supernus Pharmaceuticals Announces Participation in March Investor Conferences - Quiver Quantitative
0.21%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):